Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.61 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | BLM | P54132 | 2/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | RGS12 | O14924 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28492275 | 0.86 | ESR1 (0.63) | ESR1ESR2GAATDP1TSHR | |
| SCHEMBL30523685 | 0.84 | HPGD (0.68) | ESR1ESR2GAATDP1TSHR | |
| SCHEMBL1362192 | 0.84 | HPGD (0.68) | ESR1ESR2GAATDP1TSHR | |
| SCHEMBL12900623 | 0.83 | LMNA (0.46) | GAAPOLBLMNAALDH1A1 | |
| SCHEMBL1070431 | 0.83 | KDM4E (0.67) | ESR1GAATDP1TSHRNFKB1 | |
| SCHEMBL27907765 | 0.83 | KDM4E (0.67) | ESR1GAATDP1TSHRNFKB1 | |
| SCHEMBL23276708 | 0.82 | ESR1 (0.59) | ESR1ESR2GAATDP1TSHR | |
| SCHEMBL2796509 | 0.82 | ESR1 (0.59) | ESR1ESR2GAATDP1TSHR | |
| SCHEMBL1696094 | 0.81 | ESR1 (0.57) | ESR1ESR2TDP1KDM4ELMNA | |
| SCHEMBL8733751 | 0.81 | ESR1 (0.57) | ESR1ESR2GAATDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1701949-B1 | ASSAY FOR ENTACTOGENS | SIEMENS HEALTHCARE DIAGNOSTICS INC (US) | 2018-04-18 | — | — | EP | disclosed |
| EP-2900654-A1 | TETRAZOLINONE COMPOUNDS AND THEIR USE AS PESTICIDES | Sumitomo Chemical Company Limited (JP) | 2015-08-05 | — | — | EP | disclosed |
| US-8765809-B2 | Ester derivative and use thereof | AJINOMOTO CO., INC. (JP) | 2014-07-01 | — | — | US | disclosed |
| EP-1701948-B1 | ASSAY FOR ENTACTOGENS | SIEMENS HEALTHCARE DIAGNOSTICS (US) | 2014-03-26 | — | — | EP | disclosed |
| US-20130053441-A1 | NOVEL ESTER DERIVATIVE AND USE THEREOF | AJINOMOTO CO., INC. (JP) | 2013-02-28 | — | — | US | disclosed |
| EP-1701948-A4 | ASSAY FOR ENTACTOGENS | SIEMENS HEALTHCARE DIAGNOSTICS (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2008154023-A1 | NOVEL USES OF PPAR DELTA AGONISTS | CERENIS THERAPEUTICS S.A. (FR) | 2008-12-18 | — | — | WO | disclosed |
| EP-1701949-A4 | ASSAY FOR ENTACTOGENS | DADE BEHRING INC (US) | 2008-02-20 | — | — | EP | disclosed |
| EP-1863772-A1 | AMIDE DERIVATIVES AS PPAR ACTIVATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-12-12 | — | — | EP | disclosed |
| WO-2007028424-A1 | AMIDE DERIVATIVES AS PPAR ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-15 | — | — | WO | disclosed |
| EP-1701948-A1 | ASSAY FOR ENTACTOGENS | DADE BEHRING INC. (US) | 2006-09-20 | — | — | EP | disclosed |
| EP-1701949-A2 | ASSAY FOR ENTACTOGENS | DADE BEHRING INC. (US) | 2006-09-20 | — | — | EP | disclosed |
| US-6991911-B2 | Assay for entactogens | DADE BEHRING INC. (US) | 2006-01-31 | — | — | US | disclosed |
| WO-2005058864-A1 | ASSAY FOR ENTACTOGENS | DADE BEHRING INC. (US) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005058865-A2 | ASSAY FOR ENTACTOGENS | DADE BEHRING INC. (US) | 2005-06-30 | — | — | WO | disclosed |
| US-20050130243-A1 | Assay for entactogens | SIEMENS HEALTHCARE DIAGNOSTICS INC. | 2005-06-16 | — | — | US | disclosed |
| US-20050130244-A1 | for detection of 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxy-methamphetamine (MDMA) anibody production; drug screening; haptens; immunogens | SIEMENS HEALTHCARE DIAGNOSTICS INC. | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053441-A1 | NOVEL ESTER DERIVATIVE AND USE THEREOF | MEP1A, CES2, MEP1B | ESR1 14/4885ESR2 122/4885GAA 3440/4885 |
| US-20050130243-A1 | Assay for entactogens | HTR3C, COMT, PNMT | ESR1 1577/4885ESR2 1926/4885GAA 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.